A case of advanced thymic carcinoma that was resected after concurrent chemoradiotherapy.
- Author:
Hyun Woo LIM
1
;
Myung Jun LEE
;
Jeong Ho PARK
;
Joo Ho PARK
;
Sun Young LEE
;
Hyun Jung JUN
;
Do Yeun CHO
Author Information
1. Department of Internal Medicine, Konyang University College of Medicine, Daejeon, Korea. dycho@kyuh.co.kr
- Publication Type:Case Report
- Keywords:
Thymic carcinoma;
Paclitaxel;
Cisplatin;
Neoadjuvant chemoradiotherapy;
Surgery
- MeSH:
Aged;
Chemoradiotherapy;
Chemotherapy, Adjuvant;
Cisplatin;
Humans;
Lymph Nodes;
Paclitaxel;
Prognosis;
Thymoma
- From:Korean Journal of Medicine
2010;78(5):645-649
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Thymic carcinoma is a rare, but aggressive, tumor that often metastasizes to regional lymph nodes and distant sites and often has a poor prognosis. Although the efficacy of induction therapy in thymic carcinoma is unclear, we report the clinical course of a patient who underwent complete surgical resection after effective induction chemoradiotherapy. A 66-year-old man was diagnosed with a poorly differentiated thymic carcinoma (Masaoka stage III). The tumor was considered unresectable due to sternal invasion and surrounding fat infiltration. Two cycles of chemotherapy, consisting of paclitaxel (180 mg/m2 on D1) and cisplatin (80 mg/m2 on D1) combined with mediastinal radiotherapy (total 50 Gy) were performed concurrently; the mass decreased to a resectable size. Subsequently, he received adjuvant chemotherapy and adjuvant radiation therapy. He is currently alive and ambulatory and has remained disease-free for 19 months. This case demonstrates that induction chemoradiotherapy with paclitaxel and cisplatin may be tolerated and useful for patients with locally advanced thymic carcinoma.
